TickerTalks
Browse all tickers →
TickerTalks›$BFLY
BFBFLY

Butterfly Network, Inc.

Hot onWhy it's trendingX chatter spiked vs its recent normMoving on elevated volumeBacked by solid revenue growth
$BFLY·$2.3B·Medical - Devices·Healthcare
$8.90+55.9%YTD+129.4%1Y+327.9%
Mentions · last 7 days
2026-06-13: 9 posts2026-06-14: 7 posts2026-06-15: 32 posts2026-06-16: 34 posts2026-06-17: 45 posts2026-06-18: 466 posts2026-06-19: 135 posts731+22%
Price updated 19h ago·X counts updated 19h ago
BFBFLY
Butterfly Network, Inc.$BFLY
$8.90+55.87%731 posts+22%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BFLY, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-06-20

The move is getting stronger, with heavier trading behind it.

Portable-ultrasound name ripped 56% today on the Midjourney medical-pivot deal — and Chief Commercial Officer dumped $1.9M two weeks ago.

Butterfly Network makes the Butterfly iQ ultrasound — a handheld, smartphone-connected probe that replaces the entire ultrasound-cart workflow with the company's proprietary Ultrasound-on-Chip silicon. The big news: Midjourney's medical pivot will use 40 Butterfly Ultrasound-on-Chip modules in its full-body ultrasound scanner, with an existing supply deal worth up to $74M over five years — sending the stock 56% higher today toward four-year highs. The numbers are still pre-profitable: Q1 revenue grew 25% year-over-year to $26.5M at a -51% operating margin. The stock is up 327% TTM and 129% YTD, sitting in the 99.5th percentile of its 52-week range with a 12.85x volume multiplier — that's deal-driven euphoria, not steady accumulation. CCO Steve Cashman sold combined $1.9M on June 5 and June 8 — right before the Midjourney announcement made his exit look badly mistimed.

Agrees with X sentimentThe X bull thread on the Midjourney full-body-ultrasound scanner using 40 Butterfly Ultrasound-on-Chip modules within an existing deal worth up to $74M over five years, plus the 50% rally toward four-year highs framing Butterfly as 'the eyes of Midjourney's medical pivot' is reading the live catalyst correctly. The corpus doesn't engage with the CCO Cashman $1.9M June 5-8 selling cluster.

What to watch: Confirmation of FDA and CMS reimbursement framework for the Midjourney full-body-scanner use case — those were explicitly flagged in the news as open questions. July 31 Q2 earnings — does revenue growth re-accelerate above 30% YoY and does operating margin step toward break-even on the Midjourney chip volumes? Any further CCO selling is the structural risk.

On the calendar: 2026-07-31 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment27 posts analyzed · as of 2026-06-19

Posts surged on Midjourney's full-body ultrasound scanner using 40 Butterfly Ultrasound-on-Chip modules, with an existing deal worth up to $74M over five years. Shares rallied roughly 50 percent toward four-year highs as authors frame Butterfly as the eyes of Midjourney's medical pivot.

Read the AI verdict + X sentiment for $BFLY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Butterfly Network, Inc. functions as a digital health enterprise, specializing in the invention, production, and global commercialization of cutting-edge ultrasound imaging technologies for both domestic and international markets. The company's innovative product portfolio includes the portable Butterfly iQ, a versatile single-probe system capable of whole-body ultrasound imaging, and the Butterfly iQ+, a point-of-care ultrasound device engineered to connect effortlessly with smartphones, tablets, and existing hospital computer networks. Additionally, Butterfly Blueprint is offered as a comprehensive, system-wide ultrasound platform that seamlessly integrates its proprietary Compass software into a healthcare provider's clinical and administrative infrastructure. These ultrasound systems, encompassing probes, related accessories, and software subscriptions, are supplied to healthcare systems, individual physicians, and other medical professionals through a multi-channel distribution strategy that includes a direct sales force, a network of distributors, and an e-commerce platform. Beyond its hardware, Butterfly Network provides a suite of cloud-based software solutions for healthcare organizations. These offerings feature teleguidance services, interactive in-app educational modules, and structured training programs delivered via its Butterfly Academy software, all complemented by dedicated clinical support and services. Established in 2011, Butterfly Network, Inc. has its corporate headquarters situated in Guilford, Connecticut.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $BFLY.

Medical - Devices · Healthcare

Robotic surgery is the durable secular driver — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics as standard-of-care infrastructure. A medtech stock that 'will soar 65%' framing circulating on X this week signals analyst conviction in a device name outside the robotics narrative; ABT's decline despite market improvement highlights the GLP-1 headwind risk for metabolic device segments.

Industry benchmark

10-name peer basket
-15.7%YTD
-7.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-30.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-35.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-79.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
22.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-36.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
49.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$-0.03$-0.04+25.0%
Q4 2025Feb 26, 2026$-0.02$-0.04+50.0%
Q3 2025Oct 31, 2025$-0.13$-0.07-85.7%
Q2 2025Aug 1, 2025$-0.06$-0.07+14.3%
Next earningsFri, Jul 31·consensus EPS $-0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$26.5M+25.0%68.9%-50.8%$-0.05$-14.8M
Q4 FY25$31.5M+41.0%67.3%-61.8%$-0.06$7.9M
Q3 FY25$21.5M+4.5%-17.5%-151%$-0.13$-3.9M
Q2 FY25$23.4M+8.8%63.7%-68.9%$-0.06$-8.1M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$118.8M$116.5M – $123.2M-$0.13-$0.13 – -$0.123
FY27$142.3M$139.5M – $147.5M-$0.09-$0.10 – -$0.093
FY28$153.8M$153.4M – $154.1M-$0.06-$0.06 – -$0.062
FY29$180.0M$176.5M – $186.6M$0.00$0.00 – $0.001
FY30$220.0M$215.7M – $228.0M$0.00$0.00 – $0.001

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.12.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.99%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+82.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+151.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 192.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today31.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.205-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 8Steve CashmanChief Business Officer294.7K sh$1.4MSellJun 5Steve CashmanChief Business Officer104.8K sh$520KSellJun 2Nicholas CaezzaDeputy General Counsel1.7K sh$8KSellMay 1Megan CarlsonCAO and SVP, Finance110.4K sh$524KSellApr 29Steve CashmanChief Business Officer147.5K sh$724KSellApr 16Steve CashmanChief Business Officer200.0K sh$1.0MSellMar 5Joseph DevivoCEO482.1K sh$1.8MSellMar 3Steve CashmanChief Business Officer42.5K sh$158KSellMar 3Joseph DevivoCEO161.3K sh$599KSellMar 3Nicholas CaezzaDeputy General Counsel14.2K sh$53K
1–10 of 20
+ 7 other (7 awards) in window

See when $BFLY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMay 213
AI summary

Caroll H. Neubauer filed an initial Form 3 as a new director at Butterfly Network (BFLY) on May 21, 2026, reflecting his appointment to the board effective May 18, 2026. This is a routine new-director ownership disclosure with no open-market transactions reported.

8-KOfficer or director changeMay 88-K — Item 5.02: Officer or director change
AI summary

Butterfly Network (BFLY) disclosed that Dr. Erica Schwartz resigned from its board contingent on her Senate confirmation as CDC Director (nominated by President Trump on April 16, 2026). To fill the vacancy, Caroll H. Neubauer was appointed to the board effective May 7, 2026. The resignation and replacement are tied to a high-profile government appointment.

SC 13D/AActivist amendmentMar 17SC 13D/A
SC 13D/AActivist amendmentFeb 17SC 13D/A
8-KListing / delisting noticeJan 148-K — Item 3.01: Listing / delisting notice
+ 13 other (3 earnings 8-Ks · 3 13Gs · 2 proxys · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Butterfly Network (BFLY) Soars 55.9%: Is Further Upside Left in the Stock?zacks.com·1d agoButterfly Network Climbs On Midjourney Hype Despite FDA, Reimbursement Questionsbenzinga.com·2d agoButterfly Network Provides Commentary on Midjourney Medical's Full Body Ultrasound Scanner Announcementgurufocus.com·2d agoButterfly Network Provides Commentary on Midjourney Medical's Full Body Ultrasound Scanner Announcementbusinesswire.com·2d agoButterfly Network to Participate in TD Cowen's Medical Devices Emerging Growth Call Series on June 18, 2026gurufocus.com·9d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LAB$BIO$TMDX$CLPT$ABT$BSX$ECOR$ISRG
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport